Wait. Pause. Look a little deeper. One my my friends and colleagues, Jeffrey Lacasse, published a letter in JAMA offering some dialectical discussion on this as well as another letter in BMJ after they'd discovered that the researcher failed to disclose funding provided by the maker of the drug. One consumer advocate writes in detail about the draconian sequel that ensued, directed toward Leo and Lacasse.
Ah, the quandary. I will resist the urge to amass evidence, often under-reported, regarding duplicitous relationships and the ethical implications of such travesties.
Instead, I offer my thoughts on our proclivities toward the short-cut to healing. In sum, there is no way to bypass suffering as a part of the human condition. Clinical depression that is endogenous is vastly different from that which rises from the exogenous, a particularly traumatic event or circumstance. Yet, some fail to recognize this, and in so doing, they marginalize some of the most important healing potentialities of the human condition: people. Whether it be in the psychotherapeutic relationship or generalized social support vis-a-vis friends and neighbors, you simply cannot compare the benefits of positive human relationships with psychopharmaceuticals. Trying to do so, I would posit, is not only inherently dangerous to the individual who is depressed, but it also abdicates the responsibility that we all have to care for one another and to take the time to really be with each other through the ebb and flow of life.
There simply is no pill that can act as a proxy. There is no pharmacy that can fill the visceral need for compassionate interactions with other humans. There is no panacean riposte. Instead, the answer to human suffering is both within us and between us.